Stock ZNTL ZENTALIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Real-time Estimate Cboe BZX
Other stock markets
 12:14:31 2024-06-14 pm EDT 		5-day change 1st Jan Change
9.06 USD -4.83% Intraday chart for Zentalis Pharmaceuticals, Inc. -14.97% -40.40%
May. 29 Zentalis Pharmaceuticals, Inc. Announces Appointment of Luke Walker, M.D., to Board of Directors and Audit Committee of the Board CI
May. 24 Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
AQ
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
AQ
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
AQ
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
AQ
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS Inhibitors at AACR Annual Meeting 2024
AQ
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
AQ
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
AQ
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
AQ
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Zentalis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZNTL Stock
  4. News Zentalis Pharmaceuticals, Inc.
  5. Press Releases